EU Drug Regulator Panel Recommends Eight New Medicines Including Merck's Keytruda and AbbVie’s Maviret
An expert panel of the EU drug regulator recommended eight new medicines for approval, including expanded indications for Merck's (MRK) cancer drug Keytruda and AstraZeneca's Enhertu. AbbVie’s (ABBV) hepatitis C therapy, Maviret, was also endorsed.
